Resistance to 5-aza-2’-deoxycytidine in Genic Regions Compared to Non-genic Repetitive Sequences

（遺伝子領域の対 DNA メチル化阻害剤抵抗性）
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contents</td>
<td>1</td>
</tr>
<tr>
<td>General Introduction</td>
<td>2</td>
</tr>
<tr>
<td>Chapter 1: Resistance to 5-aza-2’-deoxycytidine in Genic Regions</td>
<td>8</td>
</tr>
<tr>
<td>Compared to Non-genic Repetitive Sequences</td>
<td></td>
</tr>
<tr>
<td>Chapter 2: Epigenetic Status of \textit{Tgfbi} Gene</td>
<td>39</td>
</tr>
<tr>
<td>General Discussion</td>
<td>75</td>
</tr>
<tr>
<td>References</td>
<td>81</td>
</tr>
<tr>
<td>Abstract</td>
<td>89</td>
</tr>
<tr>
<td>Abstract (Japanese)</td>
<td>92</td>
</tr>
</tbody>
</table>
GENERAL INTRODUCTION
General Introduction

Epigenetics is defined as heritable changes in phenotype or gene expression that does not involve changes in DNA sequence. Emergence of epigenetics provides explanation on various biological phenomena which could not be explained by genetic principles. An example of the epigenetic event is cellular differentiation, in which a vast majority of cells with identical genotype could give rise to a diversity of cell types with distinct cellular functions. Other epigenetic phenomena include imprinting of specific paternal or maternal loci in mammals (certain genes are expressed in a parent-of-origin-specific manner) and position effect variegation in the fruit fly Drosophila (in which the local chromatin environment of gene determines its expression).

In mammals, epigenetic mechanisms involve covalent modifications in DNA and in nucleosome, a fundamental chromatin unit which is composed of eight core histones (H3, H4, H2A, H2B) around which 147 base pairs of DNA are wrapped. DNA methylation comprises of attachment of a methyl group onto the fifth position of the cytosine ring of DNA, which occurs almost exclusively on CpG dinucleotide. DNA methylation is mediated by DNA methyltransferases (Dnmt). Several kinds of Dnmt have been discovered, and each Dnmt has preference on certain genomic regions (Hattori et al. 2004b). Heavily methylated DNA is associated to gene silencing. Histone modification refers to covalent modification of the amino acid residues of histone N-terminal tails which involves methylation, acetylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination and proline isomerization (Kouzarides 2007). Functional effects of histone modification depend on the position of
the modified amino acid residue and also types of the modification. For instance, histone 3 lysine 9 (H3K9) methylations are usually found in heterochromatic regions whereas histone 3 lysine 4 (H3K4) methylation and histone 3 acetylation are associated with active transcription (Fig. GI-1).

Epigenetic modifications are dynamic and changeable throughout the life span. Oct-4, a stem cell marker, has a low DNA methylation level and a high histone acetylation level in undifferentiated cells. When cells differentiate, it becomes heavily methylated and silenced (Hattori et al. 2004). Aberrant epigenetic modifications or epimutations, result in various diseases. Heavy methylation in tumor suppressor genes or demethylation in oncogenes associates with cancer. Abnormal methylation in imprinting control regions caused deregulation of imprinting and chromosomal instability that leads to Fragile X syndrome and ICF syndrome (Warren et al. 2007; Matarazzo et al. 2009). Epimutations are further complicated with diverse relationships between DNA methylation and histone modifications, contributing to the varieties of epigenetic disorder.

By reversing the aberrant epigenetic modifications to their original states, epigenetic therapy provides treatment options for epigenetic disorders. Many agents that alter methylation patterns on DNA or the modifications of histones have been discovered, and some of these agents have recently been approved for cancer treatment (Table GI-1). One of these, 5-aza-2’-deoxycytidine (5azadC), have shown promising response rate in patients with myelodysplastic syndrome and chronic myeloid leukemia along with a reversal of p15 hypermethylation in bone marrow (Hackanson et al. 2005). Although the
epigenetic drugs could reverse epigenetic status of target genes, possibility to disturb balance of the other epigenetic modifications, remains a doubt.

In this thesis, I addressed questions regarding the effect of 5azadC, a DNA methyltransferase inhibitor, on different genomic regions. In Chapter 1, I investigated the epigenetic effect of 5azadC on non-genic repetitive sequences and genic regions. Studies in Chapter 2 focused on the role of DNA methylation and histone modifications in controlling *Tgfbi*, a gene associated in corneal development, and the possible mechanisms involved in resistance of genic regions to 5azadC. Understanding the epigenetic mechanisms allows proper use of the epigenetic drug in treating *Tgfbi* associated disorders.
Figure GI-1. DNA methylation and histone modifications in epigenetic mechanisms. Both DNA methylation and histone modification regulate gene expression. Hypermethylation in CpG sites is associated with gene silencing whereas actively transcribed genes have hypomethylated CpGs. Condensed chromatin states which contain less acetylation and histone H3K4 methylation but high level of H3K9 and H3K27 methylations are transcriptionally inaccessible and vice versa (Adapted from Ohgane et. al 2008).
Table GI-1. Epigenetic drugs used in the clinic.

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DNA methylation inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>5-azacytidine (FDA approved)</td>
<td>MDS, AML, CML</td>
</tr>
<tr>
<td>5-aza-2’-deoxycytidine (FDA approved)</td>
<td>AML, CML, MDS</td>
</tr>
<tr>
<td>MG98</td>
<td>Renal cell carcinoma</td>
</tr>
<tr>
<td>RG108</td>
<td>Colon cancer cell line</td>
</tr>
<tr>
<td>Procainamide</td>
<td>Colon cancer cell line</td>
</tr>
<tr>
<td><strong>HDAC inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>SAHA (FDA approved)</td>
<td>CTCL, various solid tumors</td>
</tr>
<tr>
<td>PXD101</td>
<td>Various solid tumors</td>
</tr>
<tr>
<td>LBH589</td>
<td>CTCL</td>
</tr>
<tr>
<td>Depsipeptide</td>
<td>Multiple cancer cell lines, MDS, AML</td>
</tr>
<tr>
<td>Phenylbutyrate</td>
<td>MDS</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Neuroblastoma cells</td>
</tr>
<tr>
<td>MS-275</td>
<td>Prostate cancer cell lines, various solid tumors and lymphoid malignancies</td>
</tr>
<tr>
<td>CI-994</td>
<td>Various solid tumors</td>
</tr>
</tbody>
</table>

FDA, Food and Drug Administration; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HDAC, histone deacetylase; SAHA, suberoylanilide hydroxamic acid; CTCL, cutaneous T-cell lymphoma. (Adapted from Cortez and Jones 2008).
CHAPTER 1

Resistance to 5-aza-2’-deoxycytidine in Genic Regions Compared to Non-genic Repetitive Sequences
Chapter 1

Introduction

DNA methylation is one of the epigenetic events associated with gene regulation and function. Hypermethylation of promoter regions of tumor suppressor genes causes silencing of the genes that lead to cancer (Herman et al. 1998; Esteller et al. 1999; Tessema et al. 2003). Thus, reversing the methylation status of gene promoters to their prevalent methylation states has become a treatment option for certain cancer types. To date, there are many types of demethylating agents that have been shown to inhibit promoter methylation and reactivate silenced genes (Creusot et al. 1982; Villar-Garea et al. 2003; Cheng et al. 2004). Some of these have been approved or are in clinical studies to be developed as cancer drugs (Cortez & Jones, 2008).

5-aza-2’-deoxycytidine (5azadC), also known as decitabine, has been widely used as a DNA methyltransferase (Dnmt) inhibitor to reverse aberrant hypermethylation (Daskalakis et al. 2002; Zhu et al. 2001). It has been approved for hematological malignancies, showing favorable results with low dose treatment (Issa et al. 2004; Jabbour et al. 2008). Known to have dual modes of action, 5azadC at low doses induces gene hypomethylation, whereas high doses of 5azadC induce cytotoxicity and cause severe side effects in patients (Lima et al. 2003; Oki et al. 2007).

Nearly 40% of the mouse genome is composed of repetitive sequences including different classes of interspersed repeats such as LINEs, SINEs, LTR elements and satellites which are mainly found in heterochromatin regions (Waterston et al. 2002). Most repeats are densely methylated, and methylation in repeats reflects the global
methylation level (Yang et al. 2004; Jeong et al. 2005). Loss of methylation in repeats causes genomic instability (Ji et al. 1997; Weber & Schubeler 2007). Conversely, genes comprise only a small portion of the genome. Tissue-dependent and differentially methylated regions (T-DMRs) are unique sequences in genic regions which are methylated depending on tissue or cell types. The T-DMRs are widely observed, including in undifferentiated embryonic stem cells, normal tissues and even in cloned mice (Shiota et al. 2002; Hattori et al. 2004a; Ohgane et al. 2004; Yagi et al. 2008). Both repetitive regions and T-DMRs serve as important markers for methylation analysis, as the repeats could be used to estimate global methylation, whereas T-DMRs could serve as references for cell- or tissue-specific methylation.

Reports show that Dnmts have functional cooperation on genomic regions (Liang et al. 2002; Chen et al. 2003). We reported previously that Dnmt1, Dnmt3a and 3b share targets in the same CpG islands with T-DMRs, and each Dnmt has target preferences depending on the genomic regions (Hattori et al. 2004b). Dnmt3a and 3b prefer T-DMRs of genic regions, whereas Dnmt1 prefers repetitive sequences.

5azadC exerts its demethylating effect by binding to Dnmts (Creusot et al. 1982). Since Dnmts have multi targets, when using 5azadC, there is the potential of having a genome-wide demethylating effect. Demethylation of non-targeted genomic regions might occur, not only in cancer cells but also in normal cells. In addition, there are diverse interactions between DNA methylation and histone modifications in euchromatic and heterochromatic regions (Lachner & Jenuwein 2002; Vermaak et al. 2003). It may be possible to induce hypomethylation-independent activation of gene
expression and downstream responses. To know whether 5azadC induce invariable
effect on different genomic regions, we investigated the effect of 5azadC on non-genic
repetitive sequences and some genic regions including T-DMRs in fibroblast cells.
Materials and Methods

Reagents, cell culture and genome extraction

All reagents were purchased from Wako Pure Chemicals (Osaka, Japan) unless stated otherwise.

NIH/3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (JRH, Lenexa, USA) and 50 unit/ml penicillin / 50 µg/ml streptomycin (Invitrogen) at 37°C, 5% CO₂ in air. Prior to treatment with 5-aza-2’-deoxycytidine (5azadC; Sigma-Aldrich, Missouri, USA; diluted with sterile water to concentrations required), cells were plated at 1×10⁵ cells/150 mm dish and cultured for 24 hr. Cells were treated with 5azadC to final concentrations ranging from 0.001 to 5 µM. 5azadC was substituted with sterile water in the untreated control. Medium was changed every 24 hr, and cells were collected after 3 days for DNA extraction.

Wild type ES cells (J1) and mutant ES cells deficient of Dnmt1 (Dnmt1⁻/⁻; c/c) and Dnmt3a, 3b (Dnmt3a⁻/⁻3b⁻/⁻; 7aabb) were cultured on gelatin coated dishes with ES medium containing 1000 U/ml leukemia inhibitory factor (Chemicon, Temecula, USA) as previously described (Hattori et al. 2004b). J1, c/c and 7aabb cells were harvested at passage numbers 32, 17 and 17, respectively.

Cells were incubated in lysis buffer (150 mM EDTA, 10 mM Tris-HCl, pH 8.0 and 1% SDS) containing 10 mg/ml proteinase K (Merck, Darmstadt, Germany) at 55°C for 20 min. Following phenol/chloroform/isoamyl alcohol extraction twice, genomic DNA was precipitated with ethanol and was dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).
Cell proliferation assay

NIH/3T3 cells were seeded into 96-well plates at $1 \times 10^3$ cells per well, 24 hr before 5azadC was added. Cells were treated with 5azadC at final concentrations of 0 (as control), 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1.0, 5.0 and 10.0 µM for 3 or 4 days at 37°C, 5% CO$_2$ in air with medium changes every 24 hr. Four hours before plate reading, 10 µl of Cell Proliferation Reagent WST-1 (Roche, Penzberg, Germany) was added. Absorbance of each sample was measured against a background control using an ELISA reader at 450 nm absorption wavelength.

Analysis of the methylation status of repetitive sequences by Southern blotting

Genomic DNA (5 µg) was digested with restriction enzyme $Msp$I (Takara, Kyoto, Japan) or $Hap$II (Takara) and was electrophoresed on a 0.8% agarose gel. Following hydrolyzation with 0.25 N HCl and denaturation with 1.5 M NaCl/0.5 N NaOH, DNA was transferred onto nylon membrane. The membrane was probed with pMO for endogenous C-type retrovirus (MoMuLV) (Genebank accession NC_001501) and pMR150 for minor satellite repeats (X14469 and X07949). Probes were labeled with Gene Images random prime labeling module (Amersham Pharmacia, UK). Hybridization and detection were performed using Gene Images CDP-star detection module (Amersham Pharmacia) according to the manufacturer’s instructions.

Bisulfite restriction mapping and sequencing

Genomic DNA, digested with $Eco$RI, was denatured by incubating with 0.3 M NaOH at 37°C for 15 min. Sodium metabisulfite (pH 5.0) and hydroquinone were added to a final concentration of 2 M and 0.5 mM respectively, and the mixture was incubated
at 55°C for 18 hr in the dark. Bisulfite modified DNA was purified with the Wizard DNA Clean-up System (Promega, Madison, US), and the bisulfite reaction was terminated with NaOH at a final concentration of 0.3 M at 37°C for 15 min. Sample was neutralized by adding NH₄OAc, pH 7.0 (3 M, final concentration) and was precipitated with ethanol. Purified DNA was dissolved in sterile water, and was amplified using Immolase (BIOLINE, Tokyo, Japan) with primer sets as follows: ODE F, 5’-TAAGGGTAGGTATATAGGTGTGGT-3’ and R, 5’-TCTACCCCCCTTTAAATCACTTTAA-3’; OPR F, 5’-TGGGTTGAAATATTGGGTTATTTT-3’ and R, 5’-CTAAAAACCAATATCCAACCATA-3’; Per1 F, 5’-GGGAAGGGGATTTTGTTATTGTAGT-3’ and R, 5’-CATAAAAACCAACAAACACCATCT-3’; Sall3 F, 5’-GGGAAGGGGATTTTGTTATTGTAGT-3’ and R, 5’-CCTAATCTACCCCAACATATACAA-3’. The PCR conditions were as follow: 95°C for 10 min, followed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min.

Oct-4 distal enhancer, Oct-4 proximal enhancer and promoter PCR products were digested with TaqI (Takara) at 65°C and Per1 and Sall3 PCR products were digested with HpyCH4IV (NEB, Ipswich, MA) at 37°C for 3hr. Restricted fragments were assessed by agarose gel electrophoresis. Images were recorded and semiquantified using ImageJ software provided by National Institutes of Health (http://rsbweb.nih.gov/ij/). Relative DNA methylation level of each genomic region was calculated by the formula:

\[
\text{DNA methylation status} \ (\%) = 100 \times \frac{I^C}{(I^{UC} + I^C)}
\]

where \(I^C\) and \(I^{UC}\) represent the
intensities of the digested and undigested bands, respectively.

For bisulfite sequencing, PCR products were cloned into pGEM T-Easy vector (Promega, Madison, USA), and 10 clones were sequenced for each sample. Primer sets used were: Oct-4 F, 5’- TGGGCTGAAATACTGGGTTCAACC-3’ and R, 5’-CTGAAGCCAGGTGCTCCAGCCATG-3’; Dpep1 F, 5’-GGTTGGGAAATTGGTTGTT-3’ and R, 5’-CAACCTACTCCTAAATCCTCCA-3’; Clu F, 5’- TAGTGAGTGGGGATGTAGTATTATGG-3’ and R, 5’-AACCCCTAAACAACCTTCAAAATTTT-3’; Igf2r F, 5’-GTNTAGATATGGTGGTAGTAGTGGG-3’ and R, 5’-CCTTAAAAATAAAAATAAACATCTTTAAA-3’, with following PCR conditions: 95°C for 10 min, followed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min.

RNA extraction and RT-PCR

Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. First strand cDNA was synthesized with SuperScript™ III First-Strand Synthesis System for RT-PCR (Invitrogen), and RT-PCR was performed using Taq DNA Polymerase (Promega) with primers as follows: Dnmt1 F, 5’-CAGGAGTGTTGAGGGAG-3’; R, 5’-GGTGTCACTGTCCGACTTGC-3’; Dnmt3a F, 5’-ACCCATGCCAAGACTCACCTTC-3’; R, 5’-TCCACCTTCTGAGACTCTCGAATCCTGC-3’; Dnmt3b F, 5’-TCAGCACCAAGGATGCTCC-3’; R, 5’-ACAGGGTACTCCTGACACATG-3’; β-actin F, 5’-TTCTACATGAGCTGCTGTTGG-3’; R,
5'-ATGGCTGGGGTGTTGAAGGT-3'; \textit{Oct-4} F-
5’-GGCGTTCCGCTTTGGAAAGGTGTTC-3’; R,
5’-CTCGAACACATCTTTCTCT-3’; \textit{Clu} F, 5’- CCAGTCGAAGATGCTCAACA-3’;
R, 5’- TGTGATGGGGTGTCAGAGTCAA-3’; \textit{Dpep1} F, 5’-
ATGCGGTATCTGACCCTCAC-3’; R, 5’- ATCTGCAAAGCGTCCTTCAT-3’; \textit{Igf2r} F, 5’-
CAACGTCTGTGGAATGTGG-3’; R, 5’- CAGCCCATAGTGTTGTGAA-3’.

PCR conditions were as follow: 95°C for 1 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 5 min.

**Chromatin immunoprecipitation (ChIP) assay**

ChIP assays were performed as described previously (Hattori et al. 2004b) using a Chromatin Immunoprecipitation (ChIP) Assay Kit (Cat. No. 17-295; Upstate Biotechnology, Lake Placid, NY), with anti-acetylated histone H3 and H4 antibodies (Cat. No. 06-599 and 06-598; Upstate Biotechnology), anti-trimethylated H3K4 and H3K9 (Cat. No. ab8580 and ab8898; Abcam, Cambridge, UK), and anti-dimethylated H3K4, H3K9 and H3K27 (Cat. No. 07-030, 07-212 and 07-452; Upstate Biotechnology). Normal rabbit IgG (Cat. No. 12-370; Upstate Biotechnology) was used as a negative control to verify immunoprecipitation specificity. PCR was performed using primers as follows: \textit{Oct-4} F, 5’- GTGAGGTGTCCGGTGACCCAAGGCAG-3’ and R, 5’- CGGCTCACCTAGGGACGTTTCACC-3’; \textit{Clu} ChIP 1 F, 5’-
TGCTCTGGAGACACAGGAAA-3’ and R, 5’- CTGGGGAAGAAAGCCAAGAT-3’; \textit{Clu} ChIP 2 F, 5’-
ATTGCAGTGATGCCAGATGA-3’ and R, 5’-
ACGCACACGAGGAGAATCTT-3’; \textit{Dpep1} F, 5’-CTCCTCTTTGTGGCTCCCTAA-3’
and R, 5'-GGCTCCACAGAGTGCCAAG-3’, with following PCR conditions 95°C for 10 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min. Amount of each PCR product on an ethidium bromide stained gel-image was evaluated using ImageJ software.
Results

Demethylating effect of 5azadC on repetitive sequences

We examined cell survival under different concentrations of 5azadC by WST-1 assay. After 72 hr, viable cell number was largely reduced at concentrations at and higher than 0.5 µM, and was severely affected at higher concentrations (Fig. 1A). A similar effect was observed in the 96 hr culture. Only minimal effects on viability were observed on cells treated with less than 0.1 µM 5azadC.

To determine the effect of 5azadC on the methylation of repetitive sequences, cells were treated with 0.001 µM to 5 µM 5azadC, and the methylation status of repetitive sequences was analyzed using methylation-sensitive restriction enzymes. Southern hybridization was performed using two probes of differentially localized repetitive sequences, minor satellite repeats which are located in the centromeric regions and endogenous C-type viruses which are interspersed across the mouse genome (Joseph et al. 1989; Waterston et al. 2002; Hattori et al. 2004b). Minor satellite repeats were demethylated extensively starting at the 0.1 µM concentration (Fig. 1B), and 1 µM was sufficient to induce a maximum demethylating effect. Similarly, endogenous viruses showed aggressive loss of methylation at 0.1 µM to 5 µM treatment levels, but slight demethylation could be observed at a concentration as low as 0.001 µM. Thus, the repetitive sequences were strongly demethylated by 5azadC. The results confirmed previous report that 5azadC is effective in inducing demethylation dose-dependently from 0.1 µM to 5 µM (Davidson et al. 1992).
Effect of 5azadC on genic regions

We next examined the effect of 5azadC on T-DMRs of genic regions. *Oct-4* (*Pou5f1*) has T-DMRs in the CpG rich promoter/proximal enhancer region and the distal enhancer region (Fig. 1-2A; Hattori et al. 2004a). DNA methylation status of the T-DMRs was analyzed using bisulfite restriction mapping focusing on *Taq*I restriction sites. At 0.001 and 0.01 µM 5azadC, methylation levels of the investigated regions had changed little compared to the untreated ones (Fig. 1-2B&C). A significant loss of methylation in both regions was observed at 0.1 µM, indicating that this concentration was able to induce demethylation in both genic regions and the repetitive sequences. In the 1 and 5 µM treated samples, however, both T-DMRs had nearly the same methylation levels as in the untreated control, in contrast to the extensive demethylation observed in the repetitive sequences at these concentrations.

*Sall3* has a T-DMR located at an edge of a CpG island, which is methylated in trophoblast cell lineage (Shiota et al. 2002; Ohgane et al. 2004). The T-DMR is aberrantly methylated in the placental genome of cloned mice (Ohgane et al. 2004). *Per1*, which is involved in generating circadian rhythm, has a few CpGs at the upstream promoter region. Similar to *Oct-4*, 0.001 and 0.01 µM 5azadC had minimal effects on these loci. Methylation levels decreased significantly following 0.1 µM 5azadC treatment, but were only slightly decreased at 1 µM, and remained unchanged at 5 µM.

Bisulfite sequencing was performed on several gene loci containing CpG rich promoters, including *Oct-4*. Hypomethylation of the *Clusterin* (*Clu*) promoter is associated with high gene expression in rat testis and epididymis (Rosenblit et al. 1994).
Dpep1, a renal Dipeptidase gene, has been reported as a tumor marker candidate in malignancies (McIver et al. 2004). All investigated loci had hypermethylated promoter regions in NIH/3T3 cells (Fig. 1-3A). Bisulfite sequencing results on the Oct-4 promoter region validated the restriction mapping results that 0.1 µM was more effective in inducing demethylation in genic regions compared to 1 µM. Similar dose-dependent demethylation patterns were also observed in the promoter regions of Clu and Dpep1.

We also analyzed DMR2 region of the Igf2r imprinted gene, which is differentially methylated depending on its parental origin (Stoger et al. 1993). Due to allele specific methylation, half of the clones were methylated in the untreated control. As observed in other genes, the DMR2 region appeared demethylated at 0.1 µM, but was not affected by 1 µM 5azadC.

These results provide evidence that 5azadC has a strong demethylating effect on repetitive sequences, but its effect on genic regions is limited to a certain effective dose. The expression levels of Dnmt1, Dnmt3a and Dnmt3b were not affected by 5azadC at concentrations from 0.001 to 5 µM (Fig. 1-3B), indicating that partial retention of methylation observed at high concentrations of 5azadC was not due to increased Dnmt expression.

5azadC induced a unique combination of histone tail modifications

Since 0.1 and 1 µM 5azadC showed rather unexpected, different demethylation effects on genic regions, we investigated changes in histone modifications by
performing ChIP assay with antibodies against euchromatic and heterochromatic marks. The AcH3 level in genic regions continuously declined as concentration of 5azadC was increased (Fig. 1-4A), which is in contrast to the condition in decondensed chromatin (Vermaak et al. 2003). Such changes were not observed in AcH4, which was less enriched in genic regions.

Both H3K4me2 and H3K4me3 levels increased with 5azadC treatment, in almost all investigated regions, and high levels were correlated with increased gene expression (Fig. 1-4B). Elevation of H3K4me2 in Dpep1 at 1 µM 5azadC corresponded to a remarkable transcriptional increase, and the relatively low abundance of H3K4me2 in Oct-4 promoter region at any level of 5azadC did not induce Oct-4 expression. H3K4me3 was more enriched by 0.1 µM than by 1 µM 5azadC treatment.

Heterochromatin-associated H3K9me2 and H3K27me2 marks continuously decreased with 5azadC treatment. In contrast, elevation of H3K9me3 was observed, with higher enrichment at 1 µM compared to 0.1 µM 5azadC in most regions. Altogether, 5azadC treatment at different concentrations was accompanied by a distinct combination of changes in euchromatic and heterochromatic histone marks in genic regions.

**Increase of H3K9me3 correlates with partially methylated regions**

Studies show that H3K9 methylation directs DNA methylation (Jackson et al. 2002; Tamaru et al. 2001). To date, our data showed that 5azadC induces partial demethylation, not complete demethylation in genic regions. To find out whether increased H3K9me3
is associated with DNA methylation, we investigated enrichment of H3K9 methylation in \textit{Dpep1} and \textit{Clu} promoter regions in Dnmt deficient cells. The promoter region of \textit{Dpep1} and \textit{Clu} was heavily methylated in wild type ES cells, and was demethylated in \textit{Dnmt1}^{+/−} and in \textit{Dnmt 3a}^{−/−}\textit{3b}^{+/−} (Fig. 1-5A). Increase of H3K9me3 at the genic regions in Dnmt knock out cells was not obvious as those in 5azadC treated NIH/3T3 cells (Fig. 1-5B). Therefore, increased H3K9me3 correlated with partially methylated regions, for instance, in 5azadC treated cells. Similar to 5azadC treated cells, H3K9me2 decreased in \textit{Dnmt1}^{+/−} cells, but was increased in \textit{Dnmt3a}^{−/−}\textit{3b}^{+/−} cells.
Discussion

Current results demonstrate that 5azadC has differential effects on non-genic repetitive sequence and genic regions (Fig. 1-6). Importantly, non-genic repetitive sequences are susceptible to 5azadC, whereas genic regions are only demethylated by effective low doses. Therefore, several issues are raised regarding the use of 5azadC.

Genic regions were only demethylated at effective concentrations, but not at higher concentrations. Demethylation of repetitive sequences was concentration dependent. Thus, increasing treatment dosage might not effectively induce demethylation in targeted genic regions, but will lead to genome-wide hypomethylation in non-cancer cells. Loss of methylation promotes additional genomic changes, including increased mutation rate and pericentromeric rearrangement (Ji et al. 1997; Chen et al. 1998). Thus, before using 5azadC for cancer treatment, precise doses should be determined to achieve localized hypomethylation in cancer cells, but avoid concurrent global hypomethylation in normal cells.

Some reports showed that 5azadC treatment is followed by decreased H3K9 di-methylation (Nguyen et al. 2002; Fahrner et al. 2002; Wozniak et al. 2007). Our results also showed decreased H3K9me2, but increased H3K9me3 at all genic regions after 5azadC treatment. H3K9me3, but not H3K9me2, is a mark for cytosine methylation in chromatin regions in Neurospora crassa (Tamaru et al. 2001). Thus, increased H3K9me3 might be associated with partial methylation in 5azadC treated
cells, indicating a functional difference between H3K9me2 and H3K9me3 in mammalian cells.

Unusual histone tail modifications were observed following 5azadC treatment, in contrast to their authentic roles in DNA methylation and gene silencing (Lachner & Jenuwein 2002; Vermaak et al. 2003). Such changes might reflect mechanisms to prevent full demethylation in genic regions. As DNA methyltransferases are associated with H3K9 methyltransferases (Fuks et al. 2003; Li et al. 2006), accumulation of histone methyltransferases, which confers increase in H3K9me3, may also attracts Dnmts. Recruitment of MeCPs to the methylated DNA region is associated with a co-repressor complex containing mSin3 and histone deacetylases (HDACs), causing reduction of AcH3 (Jones et al. 1998; Nan et al. 1998). Given that Dnmt1 has preference on repetitive sequence whereas Dnmt3a and 3b are in favor to gene regions (Hattori et al. 2004b), current study may reflect preference of 5azadC to Dnmt1 (Fig.1-6). Thus Dnmt3 might be associated with H3K9 methyltransferases for maintaining the methylation level in genic regions, due to the functional cooperation of Dnmt1 and Dnmt3 (Rhee et al. 2000; 2002; Hattori et al. 2004b).

Gene activation by 5azadC seems to involve complex mechanism of action, in addition to DNA demethylation (Fahrner et al.2002; Wozniak et al. 2007). We showed that genes were upregulated at 0.1 µM, and expressions were maintained or increased at 1 µM, despite higher DNA methylation levels observed at 1 µM. Although transcriptional activation could be explained by an increase of H3K4 methylation marks (Santos-Rosa et al. 2002), AcH3 concurrently decreased drastically. Interestingly,
H3K4me3 abundance was lower in the 1 µM treatment than 0.1 µM and was accompanied by DNA hypermethylation. A similar study on cancer genes suggested that histone modifications of demethylated genes do not fully recover to euchromatic states (McGarvey et al. 2006). Thus, gene activation by 5azadC seems to be more complex than the authentic model of epigenetic gene activation and silencing.

Although studies showed that toxicity of 5azadC treatment was not due to a demethylating effect (Juttermann et al. 1994), our results raise questions concerning the 5azadC-toxicity mechanism. Repetitive sequences were partially demethylated at 0.1 µM, and were extensively demethylated at 1 and 5 µM. Concurrent with demethylation, cell viability was minimally affected at 0.1 µM, but was retarded at 1 and 5 µM, reflecting that the induced cytotoxicity might be an effect of global demethylation in the repetitive sequences. In contrast, genetic regions were hypomethylated at 0.1 µM, and were methylated at 1 and 5 µM 5azadC, probably as a resistance mechanism against cell death.

This study provides an explanation of the mechanisms behind the dual modes of action of the demethylating drug 5azadC. At low concentrations, the demethylating effect is potent in both repetitive and genetic regions. At high concentrations, repetitive sequences are highly demethylated, which potentially leads to toxicity. DNA methylation in genetic regions is less affected, which might be due to histone modification changes attempting to maintain the DNA methylation level. Thus for therapeutic use, an appropriate dose of 5azadC should be chosen wisely when it is administered to patients in order to achieve targeted gene recovery and to minimize side
effects on normal cells concurrently.
Figure 1-1. Demethylating effects of 5azadC on repetitive sequences.

A, WST-1 cell proliferation assay was performed on cells treated with 5azadC at indicated concentrations for 72 and 96 hr. Cell number was estimated by the absorbance, then represented as the ratio relative to the untreated control, the absorbance of which was arbitrarily set to 100.

B, Analysis of the methylation status of repetitive sequences by Southern hybridization. Genomic DNA (5 µg), digested with HapII, was hybridized to probes for minor satellite repeats and endogenous viruses. As a control for complete digestion, DNA from the untreated control was digested with MspI.
Figure 1-2

A

Oct-4

Sall3

Per1

B

SazadC (μM) 0 0.001 0.01 0.1 1 5

Oct-4 DE

Met (%) 42.9 51.6 57.4 34.6 51.5 49.2

Oct-4 PE/P

Met (%) 60.9 60.7 68.7 35.4 67.8 71.2

Sall3

Met (%) 90.0 77.2 71.2 60.1 49.6 100

Per1

Met (%) 25.2 23.1 22.6 3.2 9.4 24.3

C

Oct-4 DE  Oct-4 PE/P  Sall3  Per1

Legend:

- Oct-4
- 0.001 μM
- 0.01 μM
- 0.1 μM
- 1 μM
- 5 μM

Unset Cut
Figure 1-2. Methylation analysis of T-DMRs by bisulfite restriction mapping.

A, Schematic diagram of T-DMRs. T-DMRs are represented by bars and CG sites are represented by vertical lines. Locations of the amplified regions relative to each respective transcription start site are as follow: Oct-4 distal enhancer (DE), -3086 to -2646; Oct-4 proximal enhancer/promoter (PE/P), -420 to +31; Sal3, +1253 to +1665; Per1, -1087 to -929. Each locus contains 2 TaqI or HpyCH4IV restriction sites, respectively (triangles).

B, Restriction mapping. PCR products were digested with restriction enzymes and electrophoresed on agarose gel. Relative DNA methylation level was calculated based on relative intensities of cut to uncut bands, indicated below each cut lane. M, marker; U, uncut; C, cut with restriction enzyme.

C, Methylation level of T-DMRs. Graph indicates methylation level of each gene locus at each concentration, represented by the means ± S.E. of 3 independent PCRs of 2 cultures. * P<0.05 (Student’s t-test).
Figure 1-3

A

Oct-4          Dpep1          Clu          Igf2r

0 μM

0.1 μM

1 μM

B

<table>
<thead>
<tr>
<th>5azadC (μM)</th>
<th>0</th>
<th>0.001</th>
<th>0.01</th>
<th>0.1</th>
<th>1</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dnmt1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dnmt3a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dnmt3b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1-3. Methylation analysis of T-DMRs by bisulfite sequencing.

A, DNA methylation analysis of 4 gene loci, Oct-4, Clu, Dpep1 and Igf2r, using bisulfite sequencing. Top panel shows location of individual CpG site (vertical lines) in genic regions amplified by PCR. The 0, 0.1 and 1 μM 5azadC treated DNA was bisulfite converted and sequenced. Methylation status of each CpG site is represented by open (unmethylated) or closed (methylated) circles.

B, Expression of Dnmt1, Dnmt3a and Dnmt3b at 0 – 5 μM 5azadC analyzed by RT-PCR. Expression level of β-actin was used as the internal control.
Figure 1-4

A

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AcH3

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AcH4

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H3K4me2

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H3K4me3

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H3K9me2

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H3K9me3

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu ChIP 1</th>
<th>Chu ChIP 2</th>
<th>IgG</th>
<th>Input</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

H3K27me2

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Dpep1</th>
<th>Chu 1</th>
<th>Chu 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>SazadC (μM)</th>
<th>Oct-4</th>
<th>Chu</th>
<th>Dpep1</th>
<th>Igf2r</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 1-4. Histone modification status following 5azadC treatment.

A, Histone modification analysis of 0, 0.1 and 1 μM 5azadC treated samples by ChIP. Analyzed regions are indicated by boxed “ChIP” in the schematic diagram in Fig. 1-3A. DNA immunoprecipitated with respective antibodies was amplified by PCR and electrophoresed (left panels). Relative intensities of PCR bands to those of the input DNA, represented by the means ± S.E. of 3 independent PCRs of 3 cultures are shown in right panels.

B, RT-PCR results of expression of each gene following 5azadC treatment.
Figure 1-5

A

Dpep1

Clu

WT

Dnmt1^−/−

Dnmt3a^−/− 3b^−/−

B

H3K9me3

H3K9me2

WT  Dnmt1^−/−  Dnmt3a^−/− 3b^−/−
Figure 1-5. DNA methylation and H3K9 methylation status of *Dpep1* and *Clu* in Dnmt knock out ES cells.

*A*, DNA methylation analysis of *Dpep1* and *Clu* by bisulfite sequencing.

*B*, Histone modification analysis. H3K9 di- and tri-methylation levels at regions shown in panel *A* assessed by ChIP. Bar chart shows relative intensities of PCR bands to those of the input, represented by means ± S.E. of 3 independent PCRs of 2 cultures.
Figure 1-6

5-aza-2' -deoxycytidine

Satellite  Repeat  Gene

Dnmt1  Dnmt3a/3b
Figure 1-6. Summary of the effect of 5azadC on repetitive sequences and genic regions.

5azadC strongly demethylates repetitive sequences (black arrow) but only demethylates genic regions at low doses (dotted arrow). The study suggests the preference of 5azadC for Dnmt1, as Dnmt1 has a functional preference for repeats whereas Dnmt3a/3b functions on genic regions (Hattori et al. 2004b).
CHAPTER 2

Epigenetic Status of *Tgfbi* Gene
Introduction

Transforming growth factor beta-induced (Tgfbi) gene, also known as Bigh3, encodes keratoepithelin, which functions in wound healing and cell adhesion. It has a role in maintaining the integrity of normal cornea. Mutations in Tgfbi which occur mainly in 5q31 position of chromosome cause cornea deposits and different kinds of cornea dystrophies (Poulaki & Colby, 2008). Tgfbi is expressed in various tissues throughout mouse embryonic development and in different organs of transgenic mice, suggesting its multiple roles in biological regulations and functions (Schorderet et al. 2000; Bustamante et al. 2008).

Previously we identified genomic loci which are target loci of Dnmts by performing restriction landmark genomic scanning (RLGS) on Dnmt1 mutant ES cells and double mutant of Dnmt3a and Dnmt3b ES cells, using NotI as a landmark enzyme (Hattori et al. 2004b). These loci emerged as spots in the RLGS profiles of both Dnmt1/-/- and Dnmt3a-/-3b-/- ES cells, indicating that they are common targets of both Dnmt1 and Dnmt3a/3b. The intensities of the spots were stronger in Dnmt3a/-3b/- ES cells compared to those in Dnmt1/-/-, showing that the levels of demethylation are more extensive in Dnmt3a/-3b/- cells than in Dnmt1/-/- cells. These implied that Dnmt3a and Dnmt3b primarily functions in methylating genic regions (Hattori et al. 2004b). Tgfbi had been identified as one of the target loci of Dnmts detected in RLGS (Hattori et al. 2004b).

Diverse covalent modifications at histone tails, known as the histone code, provide
signals for dynamic chromatic changes in between euchromatic and heterochromatic states (Strahl and Allis, 2000). Methylation of lysine 4 on histone H3 has been linked to transcriptional activation whereas lysine 9 methylation on histone H3, cause condensed chromatin structure and transcriptional silencing (Fig. GI-1). Evidences suggest the interplay between DNA methylation and histone modifications in controlling the chromatin states and gene expressions (Vermaak et al. 2003; Freitag & Selker, 2005). Changes in DNA methylation patterns in genomic regions, will cause changes in the histone modifications. Conversely, switching of the histone code also affects DNA methylation and chromatin structure.

Modifications on histone are catalysed by histone modifying enzymes. Numerous histone methyltransferases in the Suv39 subfamily of SET domain possess H3K9 catalytic activity, which include Suv39h1, Suv39h2, G9a, GLP/Ehmt1. Cells deficient in G9a methyltransferase causes reduction of DNA methylation in gene loci, retrotransposons and major satellite repeats (Ikegami et al. 2007; Dong et al. 2008). H3K9 trimethylation, mediated by histone methyltransferase DIM-5, is a mark for cytosine methylation in chromatin regions in *Neurospora crassa* whereas loss of function of H3K9 methyltransferase kryptonite causes depletion of cytosine methylation at sites of CpNpG trinucleotides (Tamaru & Selker, 2001; Jackson et al. 2002). These suggest the role of H3K9 histone methyltransferases in DNA methylation maintenance.

5azadC is commonly used in epigenetic research to reverse aberrantly methylated gene regions and to reactivate silenced genes. In similar manner, it has been used on tumor suppressor genes in cancer treatment. Despite promising results on treating
myelodysplastic syndrome, several concerns remain, mainly regarding the mechanisms and the effect of the drug. In Chapter 1, I showed the strong effect of 5azadC on non-genic repetitive sequences. The repetitive sequences became hypomethylated concentration dependently whereas genic regions were resistance to high concentrations of 5azadC. Changes in histone modification seemed to be involved to induce such resistance. To understand better of the role of histone modifications in demethylating resistance in genic regions, I studied the functional roles of Dnmts and histone methyltransferases on *Tgfbi* in Chapter 2.
Materials and Methods

Reagents, cell culture and genome extraction

All reagents were purchased from Wako Pure Chemicals (Osaka, Japan) unless stated otherwise.

NIH/3T3 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (JRH, Lenexa, USA) and 50 unit/ml penicillin / 50 µg/ml streptomycin (Invitrogen) at 37°C, 5% CO₂ in air. Prior to treatment with 5-aza-2’-deoxycytidine (5azadC; Sigma-Aldrich, Missouri, USA; diluted with sterile water to concentrations required), cells were plated at 1×10⁵ cells/150 mm dish and cultured for 24 hr. Cells were treated with 5azadC to final concentrations of 0.1 and 1 µM. 5azadC was substituted with sterile water in the untreated control. For TSA treatment, 200 nM of TSA (Sigma) were added using ethanol as carrier. Medium was changed every 24 hr, and cells were collected after 3 days for DNA extraction.

Wild type ES cells (J1) and mutant ES cells deficient of Dnmt1 (Dnmt1⁻/⁻; c/c) and Dnmt3a, 3b (Dnmt3a⁻/⁻ 3b⁻/⁻; 7aabb) were cultured on gelatin coated dishes with ES medium containing 1000 U/ml leukemia inhibitory factor (Chemicon, Temecula, USA) as previously described (24). J1, c/c and 7aabb cells were harvested at passage numbers 32, 17 and 17, respectively.

Cells were incubated in lysis buffer (150 mM EDTA, 10 mM Tris-HCl, pH 8.0 and
1% SDS) containing 10 mg/ml proteinase K (Merck, Darmstadt, Germany) at 55°C for 20 min. Following phenol/chloroform/isoamyl alcohol extraction twice, genomic DNA was precipitated with ethanol and was dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

**Bisulfite restriction mapping and sequencing**

Genomic DNA, digested with EcoRI, was denatured by incubating with 0.3 M NaOH at 37°C for 15 min. Sodium metabisulfite (pH 5.0) and hydroquinone were added to a final concentration of 2 M and 0.5 mM respectively, and the mixture was incubated at 55°C for 18 hr in the dark. Bisulfite modified DNA was purified with the Wizard DNA Clean-up System (Promega, Madison, US), and the bisulfite reaction was terminated with NaOH at a final concentration of 0.3 M at 37°C for 15 min. Sample was neutralized by adding NH₄OAc, pH 7.0 (3 M, final concentration) and was precipitated with ethanol. Purified DNA was dissolved in sterile water, and was amplified using Immolase (BIOLINE, Tokyo, Japan) with primer sets as follows: Tgfbi Bis 1 F, 5’-GGTGGTTTAGGATAATTAGGG-3’ and R, 5’-AAATACATCAACCTACTAATACAC-3’; Tgfbi Bis 2 F, 5’-GAAATTGAAATTTGAGGATTAGTTTTT-3’ and R, 5’-CCCTTATCTCATCAACCTCCA-3’; Tgfbi Bis 3 F, 5’-TTTTTTTTTGATTTTAGGTAAGGGG-3’ and R, 5’-AAAATACCATACCCACCTCTTCCATCA-3’. The PCR conditions were as follow: 95°C for 10 min, followed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 58°C for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min.
PCR products were digested with *Hha*I (Takara, Kyoto, Japan), *Acc*II (Takara) or *Hpy*Ch4IV (NEB, Ipswich, MA) at 37°C, or with *Taq*I (Takara) at 65°C for 3 hr. Restricted fragments were assessed by agarose gel electrophoresis. Images were recorded and semiquantified using ImageJ software provided by National Institutes of Health (http://rsbweb.nih.gov/ij/). For electrophoresis using microchip electrophoresis system, band area for each fragment was quantified. Relative DNA methylation level of each genic region was calculated by the formula: DNA methylation status (%) = 100×I<sup>C</sup> / (I<sup>UC</sup> + I<sup>C</sup>) where I<sup>C</sup> and I<sup>UC</sup> represent the intensities or areas of the digested and undigested bands, respectively.

For bisulfite sequencing, PCR products were cloned into pGEM T-Easy vector (Promega, Madison, USA), and 10 clones were sequenced for each sample.

**RNA extraction and RT-PCR**

Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. First strand cDNA was synthesized with SuperScript<sup>TM</sup> III First-Strand Synthesis System for RT-PCR (Invitrogen), and RT-PCR was performed using Taq DNA Polymerase (Promega) with primers as follows: *Tgfbi* F, 5’-ACCCTCACCTCCATGTACCA-3’, R, 5’-TGCTGGATGTGTTGTCGAT-3’; *β*-*actin* F, 5’-TTCTACAATGAGCTGCGTGGA-3’, R, 5’-ATGGCTGGGCTGTGCGGAT-3’; and *Dnmt1* F, 5’-CAGGAGTGTGAGAGGAGGAG-3’, R, 5’-GGTGTCACTGTCCGACTTG-3’. PCR conditions were as follow: 95°C for 1 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 54°C for *Tgfbi*,
58°C for β-actin and 60°C for Dnmt1 for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 5 min.

**Chromatin immunoprecipitation (ChIP) assay**

ChIP assays were performed as described previously (Hattori et al. 2004b) using a Chromatin Immunoprecipitation (ChIP) Assay Kit (Cat. No. 17-295; Upstate Biotechnology, Lake Placid, NY), with anti-acetylated histone H3 and H4 antibodies (Cat. No. 06-599 and 06-598; Upstate Biotechnology), anti-trimethylated H3K4 and H3K9 (Cat. No. ab8580 and ab8898; Abcam, Cambridge, UK), and anti-dimethylated H3K4, H3K9 and H3K27 (Cat. No. 07-030, 07-212 and 07-452; Upstate Biotechnology). Normal rabbit IgG (Cat. No. 12-370; Upstate Biotechnology) was used as a negative control to verify immunoprecipitation specificity. PCR was performed using primers as follows: Tgfbi Region 1 F, 5’-CTTAGCTTGGAGCCCTGATG-3’; R, 5’- AGGCACAGTATGGCACCACGTATG-3’; Tgfbi Region 2 F, 5’-GCTTAGTAGTGGCGTGGTCTG-3’; R, 5’- CGGTGCTGGTGAAAGTGAGAG-3’; and Tgfbi Region 3 F, 5’-AGATTGGGAAACCGAGTCCT-3’; R, 5’-GAGTGGAGCCGNGATCC-3’, with following PCR conditions: 95°C for 10 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 62°C for Tgfbi Region 1, 58°C for Tgfbi Region 2, 54°C for Tgfbi Region 3 for 30 sec, and extension at 72°C for 1 min, and a final extension at 72°C for 10 min. Amount of each PCR product on an ethidium bromide stained gel-image was evaluated using ImageJ software.
RNA interference

Wild type ES cells and mutant ES cells deficient of G9a and Suv39h1/Suv39h2 were transfected with siRNA duplexes (final concentration 20 nM, Dharmacon) using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. One additional round of transfection was performed under identical conditions 48 hr after the initial transfection. Cells were harvested 48 hr after the second transfection.

Protein extraction and Western blotting

Cells were lysed in RIPA buffer (50 mM Tris-HCl, pH8.0, 400 mM NaCl, 1% Nonident P-40, 1% sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 1 µg/ml aprotinin, 5 µg/ml pepstatin and 0.5 mM EDTA). Cell lysate (10 µg) was subjected to SDS polyacrylamide gel electrophoresis on 15% gel, and were transferred onto membrane using iBlot® Dry Blotting System (Invitrogen). Transferred protein was probed with anti-GAPDH (1:2000 dilution; Imgenex, San Diego) and anti-H3K4me3 (1:500 dilution; Abcam), followed by 1:5000 diluted anti-mouse and anti-rabbit immunoglobulins conjugated with horseradish peroxidase (Wako Pure Chemicals). Protein was detected using Western Lightning ECL (Perkin Elmer, Waltham, MA).
Results

Gene Structure of Tgfbi Gene and CpG Distribution

Tgfbi has a CpG island spanning across upstream promoter region, transcription start site (TSS) and exon 1 (-162 to +93 in relative to TSS), with a CpG frequency of 69.5% and CpG\text{obs}/CpG\text{exp} of 0.78 (Fig. 2-1A). Region located downstream adjacent to the CpG island (+115~+370) is also relatively rich in CpG, and there were 38 CpGs in the CpG island and the adjacent CpG rich region. The upstream region flanking -805 to -632 is moderately rich in CpG, carrying 8 CpGs within a 173 bp fragment whereas downstream region from +519 to +937 contain relative low abundance of CpG, with and 7 CpGs within a length of 418 bp. In this chapter, we tentatively named the upstream region (-805~-632) as Region I, the CpG island and the adjacent CpG rich region (-162~+370) as Region II and the downstream region (+519~+937) as Region III.

In NIH/3T3 cells, Region I was almost fully methylated (Fig. 2-1B). All 8 CpGs scattering in the upstream region were heavily methylated. Similar to Region I, Region 3 was also fully methylated, with all 7 CpGs heavily methylated in its flanking region. Compared to Region I and III, Region II was less methylated. Almost all of the CpGs in the entire CpG island were approximately 70% methylated. At the adjacent CpG rich region, the 12 CpGs immediately following CpG island were also almost 70% methylated, whereas the 3 CpGs located 3’ end of Region II were heavily methylated. Thus, Tgfbi genic regions in NIH/3T3 cells consist of a hypermethylated Region II flanking CpG island around TSS and the adjacent CpG rich region, surrounded by fully methylated Region I upstream and Region III downstream.
**Effect of 5azadC on Methylation Pattern of Tgfbi**

To address whether the hypermethylated regions are affected by 5azadC, cells were treated with 0.1 and 1 µM of 5azadC. At 0.1 µM, heavily methylated CpGs in Region I and Region III became moderately methylated (Fig. 2-1B). Region II was hypomethylated, and the methylation level was reduced to approximately 10% in both CpG island and the adjacent CpG rich region. These showed that 0.1 µM 5azadC could induce demethylation more than 50% in genic regions.

Interestingly, when we treated the cells with 1 µM 5azadC, all CpGs in Region I remained heavily methylated. The entire Region II was divided into two differentially methylated regions by 1 µM 5azadC: a fully demethylated CpG island and a hypermethylated CpG rich region consisted of 5 unmethylated CpGs and 10 heavily methylated CpGs. Region III was also less demethylated in 1 µM compared to 0.1 µM, with 2 out of 7 CpGs in the region were moderately demethylated. The results indicated that following 1 µM 5azadC treatment, Tgfbi genic regions was divided into highly susceptible CpG island and the demethylation resistant non-CpG island regions. These consistent with our previous study on T-DMRs and other genic regions that genic regions were resistant to 1 µM compared to 0.1 µM 5azadC.

**Role of DNA methyltransferases on Tgfbi**

As regions in Tgfbi were differentially demethylated by 5azadC, we wondered which Dnmt is responsible for methylation status of Tgfbi. We investigated the methylation status of Tgfbi in Dnmt1 knock out and Dnmt3a and 3b double knock out
ES cells. In wild type ES cells, the 4 CpGs located near TSS of Region I were moderately methylated, whereas the other 4 CpGs further from TSS were densely methylated (Fig. 2-2). The CpG island in Region II was almost totally unmethylated, and only a small portion of CpGs located downstream of the CpG rich region were methylated. Region III was hypermethylated in Tgfbi. There is a clear difference of the methylation pattern of Region II between ES cells and NIH/3T3 cells, indicating that the region is a unique T-DMR which involves the entire CpG island.

In Dnmt1−/− ES cells, Region II and Region III were almost completely unmethylated. The CpG rich region located downstream of Region II was also almost completely demethylated, whereas CpG island was fully demethylated. There was a slight methylation remained in Tgfbi following Dnmt1 depletion. In Dnmt3a−/−3b−/− ES cells, all regions in Tgfbi were totally unmethylated. These data indicated that CpG methylation is regulated by Dnmt1 as well as Dnmt 3a and 3b. In the absence of Dnmt1, Dnmt3a and 3b were responsible for methylation. In contrast, Dnmt1 was unable to methylate the genic regions when Dnmt3a and Dnmt3b were disrupted. Thus, treating the cells with 5azadC should mimic the intracellular preparation of Dnmt1 knock out cells, as 5azadC is an inhibitor of Dnmt1.

**Expression of Tgfbi**

Tgfbi was expressed in NIH/3T3 cells. The expression increased when the cells were treated with 0.1 µM of 5azadC (Fig. 2-3A). In 1 µM 5azadC treated cells, the expression was also increased, despite having hypermethylated genic regions. To understand the mechanisms regulating Tgfbi expression, we investigated the status of
transcriptional active chromatin associated H3K4 methylation and histone acetylation in Region II, focusing on the CpG island region around the promoter and TSS (designated ChIP2) by ChIP analysis (Fig. 2-1A). The region covering 10 hypermethylated CpGs was highly enriched with H3K4me2 and H3K4me3 in NIH/3T3 cells (Fig. 2-3B). Following 0.1 μM 5azadC treatment, H3K4me2 remained the same level as untreated control, but H3K4me3 was slightly increased in the region. When cells were treated with 1 μM 5azadC, H3K4me2 was increased in the same region, whereas H3K4me3 had similar increment as those induced in 0.1 μM. Both H3K4 marks were elevated by 5azadC treatment, which concomitant with transcriptional increase. We confirmed the involvement of H3K4me3 in the transcriptional regulation of Tgfbi in NIH/3T3 cells by gene knockdown of Wdr5, one of the structural components in the yeast Set1 complex in H3K4 histone methyltransferases (Dou et al. 2006; Fig. 2-4).

We extended ChIP analysis to Region I and Region III. In NIH/3T3 cells, region covering the 4 CpGs at the 5’ end of Region I (designated ChIP1) was also enriched with H3K4me2, and the level was concentration dependently increased by 5azadC. H3K4me3 was less enriched than H3K4me2 in the same region, and the mark was also increased by 5azadC. In Region III, region flanking the 5 CpGs at the 3’ end (designated ChIP3) had high abundance of H3K4me2 and H3K4me3. Similar to those in ChIP1 and ChIP2 regions, the H3K4 marks were also increased by 5azadC. These showed that increment of H3K4 following 5azadC treatment occurred in all genic regions in Tgfbi regardless CpG abundance.

Tgfbi gene regions were highly enriched with histone H3 acetylation mark (AcH3)
in NIH/3T3 cells. The level of AcH3 in ChIP2 region was comparatively higher than those in ChIP1 and ChIP3 regions. Meantime, histone H4 acetylation (AcH4) was low in ChIP1, and its level was even lower in ChIP2 and ChIP3. At 0.1 µM 5azadC, both acetylation marks were largely increased at the ChIP1, and were slightly increased in ChIP2 and ChIP3.

Surprisingly, following 1 µM 5azadC treatment, AcH3 level decreased in ChIP2 compared to untreated ones, although all CpGs in this region were totally unmethylated. Likewise, decrement of AcH3 was also observed in ChIP1 which contained all heavily methylated CpGs and also in ChIP3 which was partially methylated. In contrast to AcH3, AcH4 levels remained almost unaltered in all 3 regions at the same concentration. These showed that 1 µM 5azadC caused AcH3 decrease in genic regions, and the decrease is irrelevant to DNA methylation status of the genic regions. Reduction of the mark was also in contradictory to transcriptional increase induced by the concentration.

To address whether similar histone modification changes occurred following Dnmt knock out, ChIP analysis was also performed on the same regions in Dnmt deficient ES cells. In ES cells, all regions were enriched with both H3K4 marks (Fig. 2-5B). When Dnmt1 was depleted, H3K4me2 increased in all regions, with higher fold increased in ChIP1 and ChIP3. Increment of H3K4me3 was also occurred in all regions, showing identical results as observed in 5azadC treated cells. Concurrently, Tgfbi expression increased in Dnmt1^{−/−} ES cells (Fig. 2-5A). In Dnmt3a^{−/−}3b^{−/−} ES cells, H3K4me2 was minimally altered in ChIP1 and ChIP2 regions. The mark was increased in ChIP3, but in a lesser extent compared to those induced in Dnmt1^{−/−}. H3K4me3 marks were also
slightly increased in all regions. Limited increment of both H3K4 marks in $Dnmt3a^{−/−}3b^{−/−}$ corresponded to a only slight increase in the expression.

ChIP2 region had high abundance of AcH3 in ES cells. Comparatively, ChIP1 and ChIP3 had relatively low level of the same mark. Following disruption of Dnmts, the acetylation mark was reduced in all regions. Reduction of AcH3 mark was more severe in $Dnmt3a^{−/−}3b^{−/−}$ compared to those in $Dnmt1^{−/−}$. On the other hand, AcH4 was less enriched in ChIP1 region, and its abundance was even lower in ChIP2 and ChIP3 in ES cells. A drastic reduction of the mark was observed in ChIP1 in Dnmt knock out cells, whereas slight reduction occurred in ChIP2 and ChIP3. Taken together, the acetylation mark, especially AcH3, was reduced following Dnmt inhibition or disruption.

**Resistance of **Tgfbi **to 5azadC Induced Demethylation**

To gain insight into the mechanism of resistance to demethylation induced by 5azadC, we investigated the heterochromatic associated histone marks focusing on the highly resistant Region I and Region III and the demethylation sensitive Region II. Using antibodies against H3K9me2, H3K9me3 and H3K27me2, ChIP assays were performed on ChIP1, ChIP2 and ChIP3 regions.

H3K9me2 level was low in upstream region ChIP1 in NIH/3T3 cells (Fig. 2-3B). The level was lower at ChIP2 compared to the level in ChIP1, and was more reduced in ChIP3. On the other hand, H3K9me3 was minimal at ChIP2, and the level was diminished in both ChIP1 and ChIP3. Following 5azadC treatment, H3K9me2 levels at the regions were reduced, with slightly more reduction at 1 µM. Interestingly,
degradation of H3K9me2 was accompanied by increment of H3K9me3. At ChIP2, H3K9me3 was increased at 0.1 µM 5azadC, and was further increased at 1 µM. H3K9me3 was also increased at almost the same extent in ChIP1 at both concentrations. At ChIP3, the increment occurred concentration dependently. These showed that 5azadC induced demethylation might lead to the decrease of di-methylation, followed by the increase of tri-methylation of the H3K9 marks at all Tgfbi regions. Changes in the H3K9 marks were more intense in 1 µM compared to 0.1 µM. H3K27me2 was evenly enriched the regions in NIH/3T3 cells, and was minimally altered by 5azadC treatment.

In ES cells, ChIP2 flanking the CpG island barely contained both H3K9 marks, the marks were at minimal levels at the CpG island and TSS region (Fig. 2-5B). Concurrently, ChIP 1 and ChIP had higher level of both H3K9 marks compared to ChIP2, but the enrichments were relatively low compared to H3K4 and acetylation marks. In Dnmt3a<sup>−/−</sup>3b<sup>−/−</sup> ES cells, H3K9me2 increased in all regions, which were completely unmethylated. In adverse, H3K9me3 decreased severely at all regions, and the mark was depleted at ChIP2 region.

Following Dnmt1 knocked out, H3K9me2 was lightly reduced in ChIP1 and ChIP3, and was diminished in ChIP2. In contrast, H3K9me3 was maintained at almost the same level as those in wild type, which coincided with a small level of DNA methylation observed at all of the regions in Dnmt1<sup>−/−</sup> ES cells. All together, the results were in parallel with those in 5azadC induced combination, and were in contrary to those in Dnmt3a and 3b knock out cells, implying that increasing level of H3K9me3 was
associated with maintenance of DNA methylation in the genic regions.

**Role of H3K9 methyltransferase in Tgfbi**

Increase of H3K9me3 in genic regions following 5azadC treatment suggested the involvement of H3K9 methyltransferase in the resistant mechanism. To address which enzyme is responsible for the histone methylation following Dnmt1 disturbance, we transfected H3K9 methyltransferase *Suv39h1* and *Suv39h2* double knock out ES cells and *G9a* knock out ES cells with siRNA targeting on Dnmt1, and investigated DNA methylation status in *Tgfbi* regions with bisulfite sequencing.

In wild type ES cells used for *Suv39h* knock out, the CpGs in Region I had a methylation level of 81.3% (Fig. 2-6B). The CpG island of Region II was almost completely demethylated, whereas the 7 CpG located at the 3’ end of Region II was partially methylated. Region III had a methylation level of 78.6%. Overall methylation level of these regions was higher than those observed in the J1 line wild type ES cells used for *Dnmt* knock out, due to strain and genomic differences. In *Suv39h* deficient ES cells, methylation levels of Region I, II and III were similar to those observed in wild type, indicating that Suv39h methyltransferases do not intervene in DNA methylation in genic regions.

Following *Dnmt1* knocked down, CpG methylation levels in both wild type and mutant cells of each region were reduced. Interestingly, although Dnmt1 expression was reduced to 60% of the regular level (Fig. 2-6A), DNA methylation levels in Region I and III were differentially reduced in wild type and in mutant cells after *Dnmt1* knocked
down. The methylation levels of Region I and III in mutant cells after *Dnmt1* knocked down were relatively 30-40% higher than the methylation levels in wild type cells in similar conditions. DNA methylation levels in Region II were almost similar in wild type and mutant cells after *Dnmt1* knock down. These showed that a demethylation resistance was induced in non-CpG island genic regions corresponding to *Dnmt1* knock down in *Suv39h*/*- ES cells.

We next investigated the CpG methylation status in *Tgfbi* regions following *Dnmt1* knocked down in *G9a* deficient ES cells and the wild type strain (Fig. 2-7A). In the wild type ES cells, Region I had a methylation level of 40% (Fig. 2-7B). Region II was almost completely unmethylated, having a methylation level of 4%, whereas Region III was partially methylated with a methylation level of 58.9%. Intriguingly, CpG methylation level in each region decreased following G9a disruption. In *G9a*/*- ES cells, the CpG methylation level in Region I was about 10.9%, which was almost 30% lower than the level in wild type. Region II in *G9a* deficient cells was also unmethylated, whereas the CpG methylation level in Region III was 20% lower than the level observed in wild type. The data was in contrary to those observed in *Suv39h* methyltransferases, and indicated that G9a contribute to DNA methylation level in *Tgfbi*.

Following Dnmt1 knock down, the CpG methylation level in Region I was reduced to around 20% in wild type ES cells. In *G9a* disrupted cells, the methylation level was reduced from 10% to 6%. DNA demethylation in Region III was also more severe in *G9a*/*- ES cells compared to wild type when Dnmt1 was knocked down. Region II was
almost completely demethylated when Dnmt1 was disturbed, as the region was
originally hypomethylated in both kinds of cells. Thus, in contrast to Suv39h deficient
ES cells, demethylation adherent to Dnmt1 knock down in Tgfbi regions in G9a
deficient ES cells was vigorous than those in wild type ES cells. Resistance to
demethylation observed in Suv39h deficient ES cells in Tgfbi regions was not observed
in G9a deficient cells, indicating that G9a was involved in the resistance mechanisms.
Discussion

Using chemical inhibitory of Dnmt, Dnmt knock out and knock down approaches, current studies reveal the complex epigenetic mechanisms involved in regulation of Tgfbi and how 5azadC affects the epigenetic modifications. When Dnmt is inhibited by 5azadC, DNA demethylation occurs and together with H3K4 increment, gene expression increased. However, 5azadC treatment is also accompanied by increasing of repressive mark H3K9me3, which is not observed in Dnmt1⁻/⁻ cells. H3K9me3 level increased with 5azadC concentrations, concurrently leads to demethylating resistance. In addition, histone methyltransferase G9a is involved in DNA methylation maintenance in Tgfbi, which might perhaps mediate H3K9 trimethylation. Thus, mechanism actions of 5azadC in reversing silenced genes are not just simple as DNA demethylation as previously thought.

A large decrement of DNA methylation in gene region and retroelements reflects the involvement of G9a in regulation of DNA methylation (Ikegami et al. 2007; Dong et al. 2008; Tachibana et al. 2008). However, it is still a doubt whether G9a mediates recruitment of Dnmts to targeted regions or it directly methylates DNA. Although it has been reported that human G9A interacts with DNMT1 (Esteve et al. 2006), Dnmt3a and 3b had shown to induce de novo methylation on Mage-2 and Wfdc15a in mouse ES cells, which are also the target regions of G9a/GLP complex (Tachibana et al. 2008). As Dnmt1, Dnmt3a and Dnmt3b shares the same target regions, Dnmt3a and 3b might maintain DNA methylation in gene regions when Dnmt1 is disrupted. However, Dnmt1 could not regulate DNA methylation in gene regions in Dnmt3a⁻/⁻ 3b⁻/⁻ cells, due to preference of Dnmt1 to the non-coding repetitive sequences, whereas Dnmt3a and 3b
favors coding gene regions (Chapter 1, Hattori et al. 2004b). G9a might be responsible to recruit Dnmt3a and 3b to methylate genic regions when Dnmt1 is disturbed, but does not recruit Dnmt1 when Dnmt3a and 3b is disrupted, thereby results in complete demethylation.

Involvement of G9a, but not Suv39h in DNA methylation maintenance of Tgfbi had raised questions on the substrate specificity of the histone methyltransferases. G9a depletion caused dramatic decrease in H3K9me1 and H3K9me2 in the euchromatin of ES cells, whereas ES cells with disrupted Suv39h1 and Suv39h2 leads to drastic reduction in H3K9me3 in the pericentromeric regions (Tachibana et al. 2002, 2005; Lehnertz et al. 2003; Martens et al. 2005). As current results showed that H3K9me2 was decreased and H3K9me3 was increased in 5azadC treated cells, the role played by G9a still need to be elucidated. Suv39h did not contribute to DNA methylation, probably due to its functional preference on the heterochromatin regions (Lehnertz et al. 2003; Martens et al. 2005). There is a possibility that 5azadC affects G9a methyltransferase itself, reducing H3K9me2 and H3K27me2 levels and causing DNA methylation. If this is the case, increase of H3K9me3 might involve other H3K9 methyltransferases such Eset, GLP, CLL8 (Kouzarides, 2007).

Recent studies show that Tgfbi is also associated with cancer development, and it is epigenetically inactivated in various cancer cell lines (Shao et al. 2006; Shah et al. 2008). Existence of T-DMR in Tgfbi in our studies provides evidence that the T-DMR might contribute to the gene functions. Aberrant methylation in the T-DMR which covers the CpG island at the promoter region and transcription start site might caused
abnormalities and dysfunctions that involves the gene functioning such as cancers and corneal dystrophies. Tgfbi expression is induced by both demethylation and increase of H3K4 methylation. The ability of 5azadC to induce demethylation at the T-DMR followed by transcriptional increase provides a treatment option for the abnormalities. Nonetheless, appropriate concentrations should be used due to its strong effect on non-genic regions.
Figure 2-1

A

B

Region I

Region II

Region III

0 μM

0.1 μM

1 μM
Figure 2-1. DNA methylation status of Tgfbi gene.

A, Schematic diagram of the gene structure of Tgfbi gene. Upper panel shows the gene structure of Tgfbi gene, in parallel with the CpG distribution shown in the middle panel. Middle panel demonstrate the CpG frequency of Tgfbi gene (-1000 bp to +1200 bp in relative to transcription start site) and the location of CpG island. Lower panel shows the positions of CpG sites in Region I (-805 bp to -632 bp), Region II (-162 bp to +370 bp), Region III (+519 bp to +937 bp) analyzed by bisulfite sequencing. Circles and numbers indicate positions of CpGs relative to transcription start site (+1). Arrows in the bottom panel indicate the primer positions for ChIP assay. Black bar indicates CpGs which are flanked in CpG island.

B, DNA methylation status of Tgfbi gene in NIH/3T3 cells before and after treating with 5azadC analyzed by bisulfite sequencing. Methylation status is depicted by open (unmethylated) and closed (methylated) circles for each CpG site. Numbers indicate positions of CpGs relative to transcription start site (+1). Black bar indicates CpGs which are flanked in CpG island.
Figure 2-2

Region I

Wild type

Dmt1^+−

Dmt1^−−

Region II

Region III
Figure 2-2. DNA methylation status of Tgfbi gene in Dnmt knock out ES cells.

DNA methylation status of Tgfbi gene in wild type, Dnmt1\(^{-/-}\) and Dnmt3a\(^{-/-}\)3b\(^{-/-}\) ES cells analyzed by bisulfite sequencing.
Figure 2-3

A

B

C

<table>
<thead>
<tr>
<th>SsrA (μM)</th>
<th>0</th>
<th>0.1</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tgfb1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ChIP1</th>
<th>ChIP2</th>
<th>ChIP3</th>
</tr>
</thead>
<tbody>
<tr>
<td>AcH3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AcH4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>ChIP1</th>
<th>ChIP2</th>
<th>ChIP3</th>
</tr>
</thead>
<tbody>
<tr>
<td>AcH3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K27me2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[Graphs and data representation]
Figure 2-3. Effect of 5azadC on Tgfbi gene expression and histone modification status.

_A_, Expression of _Tgfbi_ at 0, 0.1 and 1 µM 5azadC analyzed by RT-PCR. Expression level of β-actin was used as the internal control.

_B_ & _C_, Histone modification analysis of 0, 0.1 and 1 µM 5azadC treated samples by ChIP. Analyzed regions are indicated by arrowed “ChIP” in the schematic diagram in Fig. 2-1A. DNA immunoprecipitated with respective antibodies was amplified by PCR and electrophoresed. Relative intensities of PCR bands to those of the input DNA, represented by the means ± S.E. of 3 independent PCRs of 3 cultures are shown in panel C.
Figure 2-4

A

<table>
<thead>
<tr>
<th>Control</th>
<th>Control siRNA</th>
<th>Wdr5 siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>H3K4me3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gapdh</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Tgfb1 expression

<table>
<thead>
<tr>
<th>Control</th>
<th>Control siRNA</th>
<th>Wdr5 siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relative expression</td>
<td>1.2</td>
<td>1</td>
</tr>
</tbody>
</table>

Legend:

- *p < 0.05
- **p < 0.01
Figure 2-4. Effect of H3K4me3 on Tgfbi expression.

A, Protein levels of H3K4me3 in mock and Wdr5 knocked down NIH/3T3 cells. Gapdh levels were used as loading control.

B, Expression level of Tgfbi in mock and Wdr5 knocked down NIH/3T3 cells.
Figure 2-5

A

|       | WT | Familial | Mice
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tgfb1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-actn</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>ChIP1</th>
<th>ChIP2</th>
<th>ChIP3</th>
</tr>
</thead>
<tbody>
<tr>
<td>AcH3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AcH4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K27me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>ChIP1</th>
<th>ChIP2</th>
<th>ChIP3</th>
</tr>
</thead>
<tbody>
<tr>
<td>AcH3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AcH4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K4me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K9me3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H3K27me2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend:
- WT
- Familial
- Familial-3'

Figure 2-5. Histone modification patterns of Tgfbi in ES cells deficient of Dnmt1, Dnmt3a and Dnmt3b.

A, Expression of Tgfbi in Dnmt1<sup>−/−</sup>, Dnmt3a<sup>−/−</sup>3b<sup>−/−</sup> ES cells analyzed by RT-PCR. Expression level of β-actin was used as the internal control.

B& C, Histone modification analysis of ChIP1, ChIP2 and ChIP3 regions in Dnmt deficient ES cells. Analyzed regions are indicated by arrowed “ChIP” in the schematic diagram in Fig. 2-1A. DNA immunoprecipitated with respective antibodies was amplified by PCR and electrophoresed. Relative intensities of PCR bands to those of the input DNA, represented by the means ± S.E. of 3 independent PCRs of 2 cultures are shown in panel C
Figure 2-6

A

B

WT

Control

81.3 %

1.0 %

40.9 %

Dnmt1 siRNA

25.0 %

2.6 %

17.0 %

Suv39h1/-

Control

87.5 %

2.1 %

59.6 %

Dnmt1 siRNA

90.9 %

2.6 %

23.9 %

Region I

Region II

Region III
Figure 2-6. Effect of Dnmt1 knock down in *Suv39h* deficient cells.

*A*, Dnmt1 knock down efficiency evaluated by real time RT-PCR. Relative expression levels are normalized to β-actin expression level of respective samples.

*B*, DNA methylation analysis on Tgfbi in *Suv39h* deficient cells transfected with siRNA targeting Dnmt1, by bisulfite sequencing. DNA methylation levels of each region, represented by percentage of methylation, were indicated.
Figure 2-7

A

WT

Control

40.6 %

4.2 %

58.9 %

Dmnt1 siRNA

18.8 %

1.6 %

26.8 %

G9α-/-

Control

10.9 %

4.5 %

36.4 %

Dmnt1 siRNA

6.2 %

2.2 %

15.9 %

Region I

Region II

Region III
Figure 2-7. Effect of Dnmt1 knock down in G9a deficient cells.

A, Dnmt1 knock down efficiency evaluated by real time RT-PCR. Relative expression levels are normalized to β-actin expression level of respective samples.

B, DNA methylation analysis on Tgfbi in G9a deficient cells transfected with siRNA targeting Dnmt1, by bisulfite sequencing. DNA methylation levels of each region, represented by percentage of methylation, were indicated.
GENERAL DISCUSSION
General Discussion

Understanding the mechanisms underlying epigenetic disorders allows more treatment options for recovery. However, considering dynamic changes and diverse interactions in between DNA methylation and histone modifications, detailed evaluation is needed before the epigenetic drugs are clinically used. This thesis shows how 5-aza-2’-deoxycytidine or decitabine, a clinically approved drug for myelodysplastic syndrome, induced distinct effect on the non-genic repetitive sequences and genic regions.

In Chapter 1, I showed that 5azadC affects both genic regions and non-targeted repetitive sequences. Its demethylating effect on genic regions is restricted on certain effective concentrations. Increasing treatment dosage might not be effective to induce demethylation in targeted gene regions, but will lead to genome-wide hypomethylation which is associated with genomic instability and cancer (Almeida et al. 1993; Ehrlich 2002; Rodriguez et al. 2006). Hypomethylation of the repetitive sequences has been reported to be associated with chronic myeloid leukemia deterioration (Roman-Gomez et al. 2005; 2008). At the same time, 5azadC treatment was accompanied by unique combination of histone modifications, including increasing level of the heterochromatic H3K9me3 mark and decreasing level of euchromatin associated AcH3. Such combination changes might contribute to the demethylating resistance observed in genic regions.

In Chapter 2, I studied how DNA methylation and post-translational histone
modifications play central roles in regulating a disease causing gene. *Tgfbi*, a gene that is associated with cornea development and tumor suppressing, has been found to be epigenetically regulated, besides causing cornea dystrophies by mutations. Maintenance of DNA methylation pattern in *Tgfbi* involved DNA methyltransferase and histone methyltransferase G9a. Expression of *Tgfbi* is perhaps influenced by DNA hypomethylation and H3K4 levels, as increment of these marks was accompanied by gene upregulation following Dnmt inhibition (Fig. GD-1). Such assumption provides explanation on how 5azadC alone can induce re-expression of certain silenced genes that do not have apparent CpG island hypermethylation (Soengas et al. 2001; Zhu et al. 2001). Although 5azadC binds directly to DNA methyltransferase, but it might also indirectly affects other enzymes such as G9a in its mechanism of action, causing H3K9me3 elevation that contribute to demethylating-resistance. It is important to minimize the disturbance of the epigenetic balance when using an epigenetic drug for treatment.

It is of interest that resistance of genic regions to 5azadC involved H3K9 methyltransferase and Dnmts. A proposed model for the resistance mechanisms in genic regions is shown in Fig. GD-2. 5azadC inhibits Dnmt1 and causes strong demethylation hypermethylated repetitive sequences and genic regions. Due to cellular response to perhaps global hypomethylation or stress environment, H3K9me3 level in genic regions was increased, mediated by G9a histone methyltransferase. As Dnmt1, Dnmt3a and Dnmt3b share target gene regions, H3K9me3 increment induced recruitment of Dnmt3a and Dnmt3b to target regions and cause re-methylation.
Current findings are important for development of 5azadC for clinical use. Its strong effect on repetitive sequences when overdosed, involvement of other epigenetic factors in its mechanism actions should be taken in account to ensure its efficiency and safety in disease treatment.
Figure GD-1. Mechanisms of gene activation by Dnmt inhibition.
Figure GD-2. Model of resistance of genic regions to 5azadC.
References


de Lima, M., Ravandi, F., Shahjahan, M., Andersson, B., Couriel, D., Donato, M., Khouri, I.,


References

Genome Res 14, 1733-1740.


cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res 62, 6456-6461.


Santos-Rosa, H., Schneider, R., Bannister, A.J., Sherriff, J., Bernstein, B.E., Emre, N.C., Schreiber,


Tachibana, M., Sugimoto, K., Nozaki, M., Ueda, J., Ohta, T., Ohki, M., Fukuda, M., Takeda, N.,


di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26, 77-90.


Resistance to 5-aza-2’-deoxycytidine in Genic Regions Compared to Non-genic Repetitive Sequences
(遺伝子領域の対 DNA メチル化阻害剤抵抗性)

Epigenetic mechanisms, which involve DNA and histone modifications, result in the heritable silencing of genes without a change in their coding sequence. Study of human diseases have been focused on genetic mechanisms, but expanding studies have shown that disturbance of the balance of epigenetic networks can cause diseases, including cancers, mental retardations and abnormal development. Thus, reversing the abnormal epigenetic alterations has offered a great potential of developing epigenetic drugs in the clinical field. However, such development has overseen the hidden pitfalls regarding the drug usage on patients, mainly on the non-specificity effect on genomic regions and biological mechanisms.

One of the epigenetic drugs, 5-aza-2’-deoxycytidine (5azadC) or decitabine, has recently approved for several malignancies. 5azadC is known to exert its effect by inhibiting DNA methyltransferases (Dnmt), constraining the enzymatic activities and results in unmethylated DNA after several replications. There are several kinds of Dnmts, each has specific preference on genomic regions. Besides, growing evidence shows direct linking of histone modification enzymes to DNA methylation and Dnmt to histone modifications. These have raised concerns on its inducing effects, in addition to DNA demethylation.

This thesis addresses questions regarding the potential of 5azadC to induce non-targeted effect on different genomic regions and on other epigenetic modifications. Understanding of such behind mechanisms is imperative to develop better therapies for disease treatment.
**Chapter 1 – Resistance of Genic Regions against 5-aza-2’-deoxycytidine Compared to Non-genic Repetitive Sequences**

5-aza-2’-deoxycytidine (5azadC) has been widely used as a Dnmt inhibitor to reverse aberrant hypermethylation. 5azadC exerts its demethylating effect by covalently binding to Dnmts. As Dnmts have multi targets, there is potential of causing genome-wide demethylating effect by using 5azadC and risk of demethylating non-targeted genomic regions might occur. In addition, there are diverse interactions between DNA methylation and histone modification in euchromatic and heterochromatic regions. Possibility to induce hypomethylation-independent activation of gene expression and downstream responses might exist. This chapter studies the effect of 5azadC on non-genic repetitive sequences and some genic regions including T-DMRs.

Considering the potential effect of 5azadC on non-targeted genomic regions in normal cells, I investigated its effect on repetitive sequences and selected gene loci, Oct-4, Sall3, Per1, Clu, Dpep1 and Igf2r, including tissue-dependent and differentially methylated regions, by treating mouse NIH/3T3 fibroblast cells with concentrations of 5azadC ranging from 0.001 µM to 5 µM. Demethylation of minor satellite repeats and endogenous viruses was concentration dependent, and they were strongly demethylated at 1 and 5 µM. In genic regions, methylation level decreased only at 0.1 µM, but was minimally altered at concentrations lower or higher, regardless of the abundance of CpG sites. Thus, repeats are strongly demethylated, but genic regions are only demethylated at effective doses.

Genes were activated by 5azadC treatment, and were accompanied by a unique combination of histone modifications in genic regions, including an increased level of H3K9me3 and a decreased level of AcH3. Increase of H3K9me3 in genic regions was not observed in Dnmt knock out cells. I identified differential effects of 5azadC on repetitive sequences and genic regions, and revealed the importance of choosing appropriate 5azadC doses to achieve targeted gene recovery and to minimize side effects in patients receiving cancer treatment.

**Chapter 2 – Epigenetic Regulation in Tgfbi**

Transforming growth factor beta-induced gene (Tgfbi) is associated with corneal development and healing, adhesion and spreading of fibroblast and tumor suppressor activity. Mutations in Tgfbi have caused different kinds of cornea dystrophies. Recent studies have revealed epigenetic defects in Tgfbi, in association in several kinds of cancers. This chapter studies various epigenetic mechanisms controlling Tgfbi, and epigenetic therapy in treating deregulation of Tgfbi is anticipated.

5azadC induced demethylation of hypermethylated regions of Tgfbi in NIH/3T3 cells. Similar to those in Chapter 1, the regions were resistant to demethylation at 1 µM compared to 0.1 µM of 5azadC, but CpG island was demethylated by both concentrations. 5azadC induced increment of H3K9me3 and a reduced level of H3K9me2. Increased of H3K4 marks corresponded to gene
upregulation.

In Dnmt knock out cells, DNA methylation of Tgfbi was severely depleted. A complete loss of methylation was observed in Dnmt3a<sup>−/−</sup>3b<sup>−/−</sup>, and was accompanied by increased H3K9me2 and a drastic decrease of H3K9me3 in Tgfbi. In Dnmt1<sup>−/−</sup> cells, a moderate level of DNA methylation remained, H3K9me3 level was maintained and H3K9me2 was decreased. Together with 5azadC results, these suggested the role of H3K9me3 in DNA methylation maintenance.

Histone H3K9 methyltransferase G9a deficient cells had a reduced DNA methylation level in Tgfbi compared to wild type, and the DNA methylation level was further reduced following Dnmt1 knock down. In contrast, Suv39h deficient did not affect DNA methylation level. Taken together, DNA methylation maintenance in Tgfbi involves both Dnmts and G9a, and that 5azadC-induced demethylation resistance might involve complicated changes governed by these enzymes.

**Discussion**

Current studies provide evidence that 5azadC has different impact on DNA methylation between non-genic regions and genic regions. Non genic repetitive sequences were strongly demethylated by 5azadC, but genic regions were only demethylated at particular concentrations and were minimally affected by higher dosage.

5azadC does not only affect DNA methylation, but also alter histone modifications with unusual combination. Of this combination of histone modifications, H3K9me2 decreased followed by increase of H3K9me3 maybe responsible for resistance of genic regions to 5azadC-demethylating activity. Since changes of H3K9me2/H3K9me3 were not observed in G9a deficient cells, and DNA methylation was reduced in G9a deficient cells and was further reduced by Dnmt1 knock down, implying that G9a is involved in 5azadC resistance mechanisms.
Abstract (Japanese)

Resistance to 5-aza-2′-deoxycytidine in Genic Regions Compared to Non-genic Repetitive Sequences

（遺伝子領域の対DNAメチル化阻害剤抵抗性）

応用動物科学専攻
平成18年度博士課程進学
氏名 リム フイ ウェン
指導教官名 塩田邦郎

ヒストン修飾などのエピジェネティック機構は、遺伝子配列の変化を伴わず、細胞世代を越えて遺伝子発現を抑制している。これまでのヒト疾患研究は、遺伝子自体の機能に焦点を当てて行われてきたが、エピジェネティックネットワークのパランスの乱れも、ガンや精神遲滞、発育異常などの病気を引き起こしうることが分かっている。したがって、このようなエピジェネティック異常を元に戻すことは、臨床研究において開発が進められているエピジェネティック薬に大きな可能性をもたらすことを示している。しかし、このようなエピジェネティック薬の開発に際しては、患者への薬の投与を考える際に見落とされがちな方法である。それは主に、遺伝子領域への非特異的な影響と生物学的なメカニズムである。

ヒストン修飾などのエピジェネティック薬は、いくつかの悪性腫瘍に対して使用することが最近許可された。ヒストン修飾薬は ヒストンメチル基転移酵素（HDAC）を阻害することが知られている。これにより ヒストン複製に伴って ヒストンの脱メチル化が起こると考えられている。乳癌例では、ヒストン修飾薬は複数存在しており、それぞれゲノム領域に特異的である。さらに、ヒストン修飾酵素が ヒストンメチル化に直接関わっていることや、逆に ヒストンをメチル化する酵素がヒストン修飾と直接関わっていることなども明らかにされつつある。

本研究では、遺伝子領域と繰り返し配列等の異なるゲノム領域によって ヒストンが疾患治療の標的としている領域以外にも影響を及ぼす可能性があるのか、また、他のエピジェネティック修飾に影響を及ぼす可能性があるのか、についての研究を行った。本研究により得られる知見は、エピジェネティック薬による疾患治療法の開発に不可欠であると考えられる。
第一章 非遺伝子領域の反復配列と比較した遺伝子領域に対するメチル化の抵抗性

メチル化は、高メチル化異常を改善するための防害剤として広く使われている。遺伝子は、遺伝子に結合することで脱メチル化を誘導する。メチルは多数の領域を標的としていることから、メチルの使用により、ゲノムワイドな脱メチル化を引き起こす可能性や、好ましくないゲノム領域の脱メチル化が起こりやすいういうリスクがある。さらに、ゲノムマシン領域とヘテロクロマチン領域において、メチル化とヒストン修飾との間には様々な相互作用がある。また、低メチル化が遺伝子発現を活性化することや、最初に活性化された遺伝子の下流での変異にも影響を与える可能性がある。この章では、非遺伝子領域の反復配列と組織性・細胞種特異的メチル化可変領域（メチル化）を含んだ遺伝子領域のいくつかについて、メチル化の影響を解析した。

正常細胞で、標的領域以外のゲノム領域でのメチル化の影響を検討するために、反復配列とケモナバル遺伝子（甲殻類、モミガシ、ナマコ、ジンベエ）について解析した。マウスの線維芽細胞である細胞で、メチルの濃度を増減してからメチル化までの範囲で加えた。マイナーサテライト反復配列と内因性ウイルスの脱メチル化はメチル化の濃度依存的で、特にメチル化レベルの減少が観察されたが、それ以外の濃度では、濃度が低い場合には高い場合にもメチル化レベルはほとんど変化せず、これは遺伝子のメチル化数にも依存していなかった。以上より、反復配列はメチル化によって強力に脱メチル化されることのに対して、遺伝子領域では有効な濃度のときにのみ脱メチル化されることが明らかになった。

解析した遺伝子領域は、メチル化によって活性化され、これに際して特定のヒストン修飾との組み合わせの変化（メチル化の増加、減少）も同時に起こっていた。一方で、欠損細胞では遺伝子領域でのメチル化レベルの増加は観察されなかった。本章での研究から、反復配列と遺伝子領域でのメチル化による影響の違いを明らかにし、標的遺伝子の活性化と共にガング治療による患者の副作用を最小限にするためには、適切な投与量を見極めることが重要であると考えられる。

第二章 メチルにおけるエピジェネティック制御

メチル遺伝子は、角膜の発達、線維芽細胞の治癒、付着や伸長、そして腫瘍抑制活性に関係している。メチル遺伝子の変異は、さまざまな角膜発達異常の原因となっている。最近の研究では、いくつかの種類のガンでメチルのエピジェネティック異常との関連性が明らかにされている。この章では、メチル遺伝子を制御している様々なエピジェネティック機構について解析し、メチル遺伝子の制御異常を緩和する処置をすることによるエピジェネ
テック治療について検討する。

DNAオーチャン細胞において、DNAのプレスの高メチル化領域の脱メチル化を誘導した。第2章と同様に、DNAオーチャン濃度がDNAの時と比較してDNAの時には、解析した領域での脱メチル化に対する抵抗性が見られた。しかし、DNAアイランドはいずれの濃度でも脱メチル化されていた。また、DNAアイランドによって、DNAレベルの増加が引き起こされ、DNAレベルは減少していた。DNAレベルの増加は、遺伝子の発現上昇と一致していた。

DNA欠損細胞では、DNAのDNAメチル化レベルは非常に低下していた。DNAアイランド細胞ではDNAでのメチル化の完全な消失が観察され、DNAの増加とDNAアイランドの著しい減少が同時に起こっていた。DNAアイランド細胞では、DNAはある程度メチル化されたまま残っており、DNAレベルは変化がなく、DNAレベルは減少していた。以下の結果から、DNAメチル化維持におけるDNAアイランドの役割が示唆された。

ヒストンDNAメチル基転移酵素であるDNAを欠損した細胞は、野生型の細胞と比較してDNAでのDNAメチル化レベルが減少していた。さらにDNA欠損細胞でDNAをノックダウンすると、DNAメチル化レベルはさらに減少していた。一方、DNAアイランド欠損細胞では、DNAメチル化レベルへの影響は観察されなかった。以上考え合わせると、DNAにおけるDNAメチル化維持にはDNAとDNAの両方に関与しており、DNAアイランドによる脱メチル化誘導への抵抗性には、これらの酵素によって制御される複雑な変化が関与しているのかもしれない。

考察

本研究では、DNAのDNAメチル化に対する影響は非遺伝子領域と遺伝子領域で異なっている証拠を得た。非遺伝子領域の反復配列はDNAによって強く脱メチル化されるが、遺伝子領域では特定のDNAの濃度でのみ脱メチル化が起こり、投与量を増やしてもほとんど影響はなかった。

DNAはDNAメチル化だけに影響を及ぼしているだけでなく、協調して働くヒストン修飾の組み合わせも変化させる。本研究で解析したヒストン修飾の組み合わせのうち、DNAの減少とそれに続くDNAの増加は、DNAの大脱メチル化活性に対する遺伝子領域の抵抗性の原因となっている可能性がある。DNA欠損細胞で、DNAのDNAアイランドの変化は観察されなかったにも関わらず、DNAメチル化レベルが減少し、DNAノックダウン細胞ではさらにDNAメチル化レベルが減少したことから、DNAはDNA抵抗性のメカニズムに関与していることが示唆された。